Pulse Biosciences, Inc. (PLSE) Reports Q2 Loss of $0.54
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pulse Biosciences Quarterly Investor Conference Call
July 31, 2018 4:00 PM EDTConference call today at 1:30 p.m. PDT / 4:30 p.m. EDT
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a clinical stage electroceutical company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, today reported recent corporate developments and financial results for the three- and six-month periods ended June 30, 2018.
Recent Developments
Announced treatment of first subjects in a study to evaluate the safety and efficacy of novel Nano-Pulse Stimulation for the treatment of Sebaceous Hyperplasia (SH), a common but difficult-to-treat... More